AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2016
Aug 26, 2016
30751_dirs_2016-08-26_f725bd87-31ed-4db1-b4d8-3a9d9e8789ed.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2016-08-25
Reporting Person: Mulligan Seamus (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-08-25 | Ordinary Shares | S | 3565.0 | $126.651 | Disposed | 1072411 | Direct |
| 2016-08-25 | Ordinary Shares | S | 9500.0 | $127.7028 | Disposed | 1062911 | Direct |
| 2016-08-25 | Ordinary Shares | S | 10283.0 | $128.9693 | Disposed | 1052628 | Direct |
| 2016-08-25 | Ordinary Shares | S | 4620.0 | $129.4174 | Disposed | 1048008 | Direct |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $126.23 to $127.22. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $127.28 to $128.27. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $128.30 to $129.29. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $129.30 to $129.93. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.